Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Publication/Presentation Date
7-1-2019
Abstract
BACKGROUND: Recent publications should have resulted in increased hydroxyurea usage in children with sickle cell disease (SCD). We hypothesized that hydroxyurea use in children with SCD increased over time and was associated with decreased acute care visits.
METHODS: This was a secondary analysis of the Truven Health Analytics-IBM Watson Health MarketScan Medicaid database from 2009 to 2015. The multistate, population-based cohort included children 1 to 19 years old with an
RESULTS: A mean of 5138 children each year were included. Hydroxyurea use increased from 14.3% in 2009 to 28.2% in 2015 (
CONCLUSIONS: There was a significant increase in hydroxyurea use in children with SCD between 2009 and 2015. However, in 2015, only ∼1 in 4 children with SCD received hydroxyurea at least once. Increases in hydroxyurea were not associated with consistently decreased acute care visits in this population-based study of children insured by Medicaid.
Volume
144
Issue
1
ISSN
1098-4275
Published In/Presented At
Brousseau, D. C., Richardson, T., Hall, M., Ellison, A. M., Shah, S. S., Raphael, J. L., Bundy, D. G., & Arnold, S. (2019). Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children. Pediatrics, 144(1), e20183285. https://doi.org/10.1542/peds.2018-3285
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31227564
Department(s)
Administration and Leadership
Document Type
Article